saracatinib   Click here for help

GtoPdb Ligand ID: 7731

Synonyms: AZD-0530 | AZD0530
PDB Ligand
Compound class: Synthetic organic
Comment: Saracatinib was developed as an inhibitor of Src family tyrosine kinases. This compound is now included in AstaZeneca's Open Innovation Pharmacology Toolbox.
Note that some bioactivity data may be associated with the difumarate salt (PubChem CID 44195703).
Saracatinib (AZD0530) is compound 33 in [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 8
Topological polar surface area 90.44
Molecular weight 541.21
XLogP 2.81
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CN1CCN(CC1)CCOc1cc(OC2CCOCC2)c2c(c1)ncnc2Nc1c(Cl)ccc2c1OCO2
Isomeric SMILES CN1CCN(CC1)CCOc1cc(OC2CCOCC2)c2c(c1)ncnc2Nc1c(Cl)ccc2c1OCO2
InChI InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31)
InChI Key OUKYUETWWIPKQR-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Saracatinib (AZD0530) was progressed as a clinical candidate. AstraZeneca discontinued development of AZD0530 in cancer indications in 2011. The compound was repurposed, notably for a range of orphan conditions [2]. The US FDA granted orphan drug designations for the treatment of idiopathic pulmonary fibrosis (IPF; in 2019) and fibrodysplasia ossificans progressiva (FOP: in 2026).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04307953 Saracatinib Trial TO Prevent FOP Phase 2 Interventional Amsterdam UMC, location VUmc
NCT04598919 Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis Phase 1/Phase 2 Interventional National Jewish Health